CHRONIC GRAFT-VERSUS-HOST-DISEASE

This study tests whether adding axatilimab to standard steroid treatment helps people with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. About 240 participants aged 12 and older will receive either axatilimab or a placebo…

This study tests whether combining a drug called axatilimab with a blood-filtering procedure (ECP) can help people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. About 49 participants who have tried at least two prior treatments will …

This study tests a drug called axatilimab in people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant where donor cells attack the patient's body. Participants must have tried at least two other treatments without success. The goal is to …

This study tests a drug called pacritinib in people with moderate or severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. cGVHD is an immune disorder that can damage organs and cause disability. Participants must be 18 or older and have not responded to …

This phase 2 trial tests whether the drug belumosudil can help people who develop bronchiolitis obliterans syndrome (BOS), a type of lung scarring, after a stem cell transplant. The study will enroll 45 participants with new or early-stage BOS. Participants will take belumosudil …

This study is tracking the safety and effectiveness of the drug JAKAVI (ruxolitinib) in 395 patients with graft-versus-host disease (GVHD), a complication of bone marrow transplants. Researchers are monitoring infections and other side effects in patients receiving the drug in ro…

This study tests whether the drug belumosudil can prevent chronic graft-versus-host disease (cGVHD) from worsening in stem cell transplant recipients. About 82 participants will receive either belumosudil or a placebo. The goal is to see if the drug delays the need for additional…

This study tests the drug belumosudil in children aged 1 to 18 who have moderate-to-severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and whose condition has not improved with at least two prior treatments. The trial has two phases: the first finds th…

This study offers continued access to the drug ibrutinib for up to 700 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) who are already taking it and benefiting. Researchers will track side effects and how the disease changes over time. Th…

This study tests a drug called axatilimab against the best available treatments for children aged 2 to 18 with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The trial enrolls 60 participants who have already tried at least two other treat…

This study tests whether adding madecassoside tablets (from the Centella asiatica plant) to standard treatment can help people with a severe form of chronic graft-versus-host disease that causes skin hardening and joint stiffness. About 30 participants aged 14 to 65 will take the…

This study tests a combination of two drugs, belumosudil and rituximab, as the first treatment for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The goal is to see if this approach can control the disease and reduce the need f…

This study tests a drug called axatilimab for people whose skin becomes thick and hard (sclerotic) after a donor stem cell transplant, a condition called chronic graft-versus-host disease. The drug aims to block immune signals that cause inflammation and scarring. About 50 adults…

This study is testing whether crushing belumosudil tablets and mixing them with water changes how the drug is absorbed in people with chronic graft-versus-host disease (cGVHD). Only 8 participants who have had a stem cell transplant will take the drug both ways and have their blo…

This study tests a drug called axatilimab in 30 Chinese patients with chronic graft-versus-host disease (cGVHD) that has come back or not improved after standard treatment. cGVHD is a complication of bone marrow or stem cell transplants where donor cells attack the patient's body…

This early-stage trial tests whether adding fostamatinib to the standard drug ruxolitinib can safely help people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a serious complication after a stem cell transplant where the donor cells at…

This early-phase trial tests an oral drug called Q702 in 18 people with chronic graft-versus-host disease (cGVHD) that has not responded to standard treatments. The main goals are to check safety, find the right dose, and see early signs of effectiveness. All participants have mo…

This study tests a new drug, rovadicitinib, for people with moderate to severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Participants must have tried at least two prior treatments. The goal is to see if rovadicitinib improves symptoms better than sta…

This study tests whether a dental cleaning shortly after a stem cell transplant can prevent chronic graft-versus-host disease (GVHD), a common and serious complication. Researchers will enroll 45 adults receiving a donor stem cell transplant for blood cancer. The goal is to see i…

This study looks at whether a home-based aerobic and resistance exercise program is feasible for adults with graft-versus-host disease (GVHD) after a stem cell transplant. Participants will either do aerobic and resistance exercises or simple stretching. The goal is to see if exe…

This study tests a group-based telehealth program called HORIZONS for adults living with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. The program includes 8 sessions led by a therapist to help with self-management and quality of life. Researchers will c…

This study tests whether a virtual exercise program can help children and young adults (ages 8-23) recover physical function and quality of life after a stem cell transplant. Participants will have twice-weekly, 30-minute online sessions with a physical therapist for 12 weeks. Th…

This study follows 650 people with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. Researchers aim to track the disease over time, identify biological markers, and improve how it is diagnosed and managed. Participants undergo regular check-u…

This pilot study is testing a new imaging agent called [18F]4FN in PET/CT scans for people with chronic graft-versus-host disease (GVHD) affecting their joints. The goal is to see if the agent is safe and can help doctors see joint problems more clearly. Sixteen adults with chron…

This study enrolls 300 adults with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy. Researchers will collect blood samples and medical data before and after treatment to look for changes that might predict how well a patient responds. The goal is to…

This study is testing a new type of MRI that uses xenon gas to see how well the lungs are working in people who have had a bone marrow transplant. Researchers will scan 25 transplant patients with or without lung problems, plus 10 healthy volunteers. The goal is to see if this MR…

This study looks at whether a special CT scan analysis called parametric response mapping (PRM) can detect early signs of chronic lung disease in people who have had a stem cell transplant. Researchers will follow 375 patients for one year to see if PRM patterns predict lung func…